Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This is a single site phase I dose escalation trial of the epidermal growth factor receptor
inhibitor Erlotinib with the SRC tyrosine kinase inhibitor Dasatinib in patients with
previously treated advanced stage (Stage IIIB/IV disease) Non-Small Cell Lung Cancer (NSCLC).
The treatment regimen consists of Erlotinib tablets starting Day 1 and Dasatinib tablets
starting Day 9 for a 28-day cycle. If there are no Dose Limiting Toxicities (DLTs), dose
escalation continues. The recommended phase II dose for this combined treatment will be
defined and patients will be treated at the recommended phase II dose to confirm
tolerability.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute